Advanced Technology Ventures was the other co-lead in the $32m B round for Verastem alongside Astellas's corporate venturing unit.
Astellas Venture Management, the corporate venturing unit of Japan-based drugs company Astellas Pharma, has co-led the $32m series B round for Verastem, a US-based biopharmaceutical company to treat breast cancer.
Advanced Technology Ventures was the other co-lead alongside Astellas, and they were joined by all Verastem’s existing investors, venture capital firms Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.
Christoph Westphal, co-founder and chairman of Verastem and Longwood, said "This financing is a recognition of the significant…
